Report Information More information from: https ://www.wis eguyreports .com/reports /495879
Lung Transplantation - Pipeline Review, H1 2016 Report / Search Code: WGR495879
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Lung Trans plantation - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Lung Trans plantation - Pipeline Review, H1 2016’, provides an overview of the Lung Trans plantation pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Lung Trans plantation, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Lung Trans plantation and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Lung Trans plantation - The report reviews pipeline therapeutics for Lung Trans plantation by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Lung Trans plantation therapeutics and enlis ts all their major and minor projects - The report as s es s es Lung Trans plantation therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Lung Trans plantation Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Lung Trans plantation - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Lung Trans plantation pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lung Trans plantation Overview 6 Therapeutics Development 7 Pipeline Products for Lung Trans plantation - Overview 7 Lung Trans plantation - Therapeutics under Development by Companies 8 Lung Trans plantation - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Lung Trans plantation - Products under Development by Companies 11 Lung Trans plantation - Companies Involved in Therapeutics Development 12 Apeptico Fors chung und Entwicklung GmbH 12 Kamada Ltd. 13 Proteo, Inc. 14 Quark Pharmaceuticals , Inc. 15 Lung Trans plantation - Therapeutics As s es s ment 16 As s es s ment by Monotherapy Products 16 As s es s ment by Target 17 As s es s ment by Mechanis m of Action 19 As s es s ment by Route of Adminis tration 21 As s es s ment by Molecule Type 23 Drug Profiles 25 alpha-1 proteinas e inhibitor (human) - Drug Profile 25 Product Des cription 25 Mechanis m of Action 25 R& D Progres s 25 FX-06 - Drug Profile 27 Product Des cription 27 Mechanis m of Action 27 R& D Progres s 27 PB-01 - Drug Profile 29 Product Des cription 29 Mechanis m of Action 29 R& D Progres s 29 QPLI-1 - Drug Profile 31 Product Des cription 31 Mechanis m of Action 31 R& D Progres s 31 R-503 - Drug Profile 32 Product Des cription 32 Mechanis m of Action 32 R& D Progres s 32 R-801 - Drug Profile 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 s olnatide - Drug Profile 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 tipreles tat - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39 Lung Trans plantation - Recent Pipeline Updates 42 Lung Trans plantation - Dormant Projects 49 Lung Trans plantation - Product Development Miles tones 50 Featured News & Pres s Releas es 50 Apr 06, 2016: Kamada Announces Initiation of Phas e 2 Clinical Trial with Intravenous Alpha-1 Antitryps in for the Prevention of Lung Trans plant Rejection 50 Jun 22, 2015: Kamada Collaborates with Baxalta on Phas e 1/2 Clinical Trial with Alpha-1 Antitryps in for the Prevention of Lung Trans plant Rejection 51 Mar 12, 2015: Elafin combined with cyclos porine promis es to overcome limitations of cyclos porine for preventing irrevers ible damage to trans planted organs 52 Apr 17, 2013: APEPTICO initiates phas e II clinical trial with AP301 in patients with
primary graft dys function following lung trans plantation 53 Dec 06, 2011: Proteo And Its Subs idiary Announce Major Advances In ElaďŹ n Development Program 53 Sep 08, 2009: APEPTICO Pres ents Lead Product AP301 At Annual Congres s Of European Res piratory Society In Vienna, Aus tria 54 Appendix 56 Methodology 56 Coverage 56 Secondary Res earch 56 Primary Res earch 56 Expert Panel Validation 56 Contact Us 56 Dis claimer 57 Lis t of Tables Number of Products under Development for Lung Trans plantation, H1 2016 7 Number of Products under Development by Companies , H1 2016 8 Comparative Analys is by Clinical Stage Development, H1 2016 9 Comparative Analys is by Early Stage Development, H1 2016 10 Products under Development by Companies , H1 2016 11 Lung Trans plantation - Pipeline by Apeptico Fors chung und Entwicklung GmbH, H1 2016 12 Lung Trans plantation - Pipeline by Kamada Ltd., H1 2016 13 Lung Trans plantation - Pipeline by Proteo, Inc., H1 2016 14 Lung Trans plantation - Pipeline by Quark Pharmaceuticals , Inc., H1 2016 15 As s es s ment by Monotherapy Products , H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanis m of Action, H1 2016 20 Number of Products by Stage and Route of Adminis tration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Lung Trans plantation Therapeutics - Recent Pipeline Updates , H1 2016 42 Lung Trans plantation - Dormant Projects , H1 2016 49 Lis t of Figures Number of Products under Development for Lung Trans plantation, H1 2016 7 Number of Products under Development by Companies , H1 2016 8 Comparative Analys is by Clinical Stage Development, H1 2016 9 As s es s ment by Monotherapy Products , H1 2016 16 Number of Products by Targets , H1 2016 17 Number of Products by Stage and Targets , H1 2016 17 Number of Products by Mechanis m of Actions , H1 2016 19 Number of Products by Stage and Mechanis m of Actions , H1 2016 19 Number of Products by Routes of Adminis tration, H1 2016 21 Number of Products by Stage and Routes of Adminis tration, H1 2016 21 Number of Products by Molecule Types , H1 2016 23 Number of Products by Stage and Molecule Types , H1 2016 23
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349